Pediatric advisory committee considers heartburn drugs
This article was originally published in The Tan Sheet
Executive Summary
FDA's Pediatric Advisory Committee will meet June 21 in Bethesda, Md., to discuss pediatric safety reviews for several drugs, including proton pump inhibitors Prevacid (lansoprazole) and Prilosec (omeprazole), according to a May 11 Federal Register notice. The notice does not specify if the drugs could be available to children in the future, but currently both products are recommended for patients 18 years and older. Comments are due June 7
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.